DYN vs. RNA, DRNA, ARWR, AMPH, PTGX, CTLT, ROIV, ELAN, ASND, and LEGN
Should you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Avidity Biosciences (RNA), Dicerna Pharmaceuticals (DRNA), Arrowhead Pharmaceuticals (ARWR), Amphastar Pharmaceuticals (AMPH), Protagonist Therapeutics (PTGX), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Avidity Biosciences (NASDAQ:RNA) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.
Avidity Biosciences has higher revenue and earnings than Dyne Therapeutics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Dyne Therapeutics had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 7 mentions for Dyne Therapeutics and 6 mentions for Avidity Biosciences. Dyne Therapeutics' average media sentiment score of 1.02 beat Avidity Biosciences' score of 0.95 indicating that Avidity Biosciences is being referred to more favorably in the media.
96.7% of Dyne Therapeutics shares are held by institutional investors. 3.7% of Avidity Biosciences shares are held by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Avidity Biosciences has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.
Dyne Therapeutics has a net margin of 0.00% compared to Dyne Therapeutics' net margin of -2,103.78%. Dyne Therapeutics' return on equity of -37.98% beat Avidity Biosciences' return on equity.
Avidity Biosciences currently has a consensus target price of $41.33, suggesting a potential upside of 53.88%. Dyne Therapeutics has a consensus target price of $40.78, suggesting a potential upside of 27.91%. Given Dyne Therapeutics' higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Dyne Therapeutics.
Avidity Biosciences received 119 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Dyne Therapeutics an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
Summary
Dyne Therapeutics beats Avidity Biosciences on 10 of the 18 factors compared between the two stocks.
Get Dyne Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dyne Therapeutics Competitors List
Related Companies and Tools
